

Featured Communications

Featured Communications 1

How can medications be used to treat substance use disorders, sustain recovery and treat drug overdose?

May 24, 2024 | 15:00-16:00 | Room 9 (G404)

Chair Yuki Moriya (Tokyo Metropolitan Institute of Medical Science)

FC1-1 **Mitochondrial dysfunction in bone density metabolism in patients with opioid use disorder under methadone maintenance treatment**

WENYU HSU (Changhua Christian Hospital)

FC1-2 **Insights into the lethal toxicity of synthetic psychoactive cathinones from studies in larval zebrafish**

Frank Scott Hall (University of Toledo)

FC1-3 **Sex differences in the reduction of hopelessness in μ opioid receptor deficient mice by additive effects of δ opioid receptor agonists**

Yuki MORIYA (Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan)

Featured Communications 2

May 25, 2024 | 10:10-11:10 | Room 10 (G402)

Chair Joseph T. Coyle (McLean Hospital and Harvard Medical School)

FC2-1 **SARS-CoV-2-Driven Epidermal Growth Factor Receptor Signaling and the COVID19-Associated Psychosis/Schizophrenia**

Hiroyuki Nawa (School of Pharmaceutical Sciences, Wakayama Medical University)

FC2-2 **Searching for the “magic pills“ for unmet medical needs in schizophrenia and other neuropsychiatric disorders: Learning from a novel DAO inhibitor.**

Wen-Sung Lai (Department of Psychology, National Taiwan University, Taipei, Taiwan)

FC2-3 **Multomic profiling of rapid antidepressant mechanisms in a rat model of depression**

Laura Musazzi (University of Milano-Bicocca)

Featured Communications 3

New players on monoaminergic field: relevance to mental disorders

May 25, 2024 | 13:15-14:15 | Room 10 (G402)

Chair Eliyahu Dremencov (Center of Biosciences, Slovak Academy of Sciences)

FC3-1 **TAAR1 agonists as potential anti-addiction candidates: preclinical evidence**

Jun-Xu Li (University at Buffalo)

FC3-2 **Ligands of the delta-opioid receptor and trace amine associated receptor 1 exert similar effects on monoaminergic transmission in rats**

Daniil Grinchii (Center of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia)

FC3-3 **Putative sex differences in the excitability of beta-endorphin and neuropeptide-Y-secreting neurons of the arcuate nucleus**

Eliyahu Dremencov (Center of Biosciences, Slovak Academy of Sciences)

Featured Communications 4

Investigation in ageing from multiple aspects among patients with mental disorders

May 25, 2024 | 14:30-15:30 | Room 4 (Hall D1)

Chair Yun-Hsuan Chang (National Cheng Kung University)

FC4-1 **The aging effect on cognitive functioning and emotional intelligence in patients with bipolar disorders**

Yun-Hsuan Chang (Institute of Gerontology, College of Medicine, National Cheng Kung University)

FC4-2 **Relationship between Alcohol -related brain dysfunction and brain perfusion SPECT**

Tomohiro Shirasaka (Teine Keijinkai Medical Center)

FC4-3 **The age effect upon fNIRS measured brain function between schizophrenia patients and normal controls**

TSUO-HUNG LAN (Tsaotun Psychiatric Center)

Featured Communications 5

May 25, 2024 | 14:30-15:30 | Room 10 (G402)

Chair Marina Picciotto (Yale School of Medicine)

FC5-1 **Long-acting injectable antipsychotic use in patients with bipolar disorder: Findings from REAP-BD study**

Shih-Ku LIN (Linkou Chang Gung Memorial Hospital)

FC5-2 **Sex- and dose-dependent catalase increase and its contribution to cognitive improvement in a benzoate dose-finding clinical trial for Alzheimer's disease**

Hsien-Yuan Lane (Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan)

FC5-3 **Adjuvant Cithicoline Against Negative Symptoms and Interleukin 6 (IL-6) In Schizophrenia Patients With Receiving Risperidone Treatment**

Andi Jayalangkara TANRA (Department of Psychiatry, Universitas Hasanuddin, Makassar, Indonesia)

Featured Communications 6

May 26, 2024 | 14:50-16:10 | Room 3 (Hall D7)

Chair Stefano Comai (University of Padova)

FC6-1 **Modulation of the dopaminergic neurotransmission by controlling the activity of tyrosine hydroxylase**

Hiroshi Ichinose (School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan)

FC6-2 **α 6GABAA receptor-selective positive allosteric modulator as a novel therapy for ADHD: A preclinical study in MK-801-treated juvenile mice**

Lih-Chu Chiou (Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan)

FC6-3 **Decoding the Link among Schizophrenia, Metabolic Syndrome, and the Serotonin/Melatonin Pathway using the MK-801 Mouse Model**

Stefano Comai (University of Padova)

Featured Communications 6

Award-winners Lectures: CIMP 2024 Excellent Presentation Award

May 26, 2024 | 15:00-16:00 | Room 8 (G405)

Chair Maria Oquendo (Perelman School of Medicine, University of Pennsylvania)

AW2-4 **Early social isolation stress potentiates heroin seeking by aggravating the dysfunction of prelimbic cortex to ventral tegmental area projection**

Zijun Wang (University of Kansas)

Short Communications

Short Communications 1

Addiction Disorders 1 - Clinical (1)

May 24, 2024 | 10:45-12:00 | Room 6 (G408)

Chair Shih-Ku Lin (Linkou Chang Gung Memorial Hospital)

SC1-1 **The Effect of Dopamine Receptor D1 (DRD1) Gene Variants on Changes in Craving Severity During Alcohol Withdrawal**

Ze-yu Lin (Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan)

SC1-2 **GxE Interaction Effects of HCRTR2 Single Nucleotide Polymorphism and Adverse Childhood Experiences on Methamphetamine Use Disorder**

Kai-Ting Chen (Department of General Medicine, Taipei City Hospital, Taipei, Taiwan.)

SC1-3 **Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder – a longitudinal structural magnetic resonance imaging study**

Zhenhao Shi (Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA)

SC1-4 **withdrawal**

SC1-5 **The cost-effectiveness of opioid agonist treatment among opioid dependent individuals: Evidence from the real-world data**

Kun Chia Chang (Jianan Psychiatric Center, Ministry of Health and Welfare, Tainan, Taiwan)

SC1-6 **Comparing Immunocytokines Levels between Alcohol-dependent Patients With and Without Delirium Tremens**

Shu Hao Hsu (Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan)

Short Communications 2

Bipolar Disorders - Clinical

May 24, 2024 | 10:45-12:00 | Room 7 (G407)

Chair Ya-Mei Bai (Taipei Veterans General Hospital)

SC2-1 **Supplementing with dextromethorphan may enhance cognitive functions in young individuals with bipolar disorders**

Chih-Chun Huang (Department of Psychiatry, National Cheng Kung University Hospital, Douliu Branch)

SC2-2 **Navigating Bipolar Disorders: Addressing Challenges in Treatment-Resistant Depression and Rapid Cycling**

Micaela Dines (Instituto de Neurologia Cognitiva (INECO))

SC2-3 **Predicting depressed and elevated mood symptomatology in bipolar disorder using brain functional connectomes**

Anjali Sankar (Copenhagen University Hospital)

SC2-4 **White Matter Abnormalities and Cognitive Impairment in Bipolar I Disorder: A Multi-State Investigation**

Ting Sun (China Medical University)

SC2-5 **The Iowa Gambling Task Net Scores is Associated with Social Function in Bipolar Disorder**

Shyh-Yuh Wei (National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University)

SC2-6 **Striatal functional connectivity pattern associated with emotional symptoms and cognitive performance in manic/hypomanic, euthymic and depressive states of bipolar disorder**

Yan-Kun Wu (Peking University Sixth Hospital)

Short Communications 3

Depression 1 - Clinical (1)

May 24, 2024 | 10:45-12:10 | Room 8 (G405)

Chair Michael Berk (Deakin University)

- SC3-1 **Subgroup Analysis in Changes in Quality of Life and Depression Severity Scores By Line of Therapy in Patients Treated with Esketamine in a Real-world Setting across ANZ**
David Barton (Brain and Mind Centre, The University of Sydney, Sydney, Australia)
- SC3-2 **The anterior cingulate cortex links serotonin transporter genetics and emotion processing**
Manfred Kloeb (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)
- SC3-3 **Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder**
Zubin Bhagwagar (Intra-Cellular Therapies Inc., New York, NY, USA)
- SC3-4 **The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds**
Livia De Picker (Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium)
- SC3-5 **Clinical and Economic Burden of Major and Treatment-Resistant Depression in a population-based study cohort of 110.000 patients**
Sofia Pappa (Department of Brain Sciences, Faculty of Medicine, Imperial College, London, United Kingdom)
- SC3-6 **Effect of tramadol as an adjunctive pharmacological treatment for Major Depressive Disorder: a randomized, double-blind, placebo-controlled trial.**
Andre Campiolo Boin (Neuroscience and Behavior Department Ribeirão Preto Medical School, University of São Paulo, Brazil)
- SC3-7 **Role of Klotho on Antidepressant and Antisuicidal Effects of Low-Dose Ketamine Infusion among Patients with Treatment-Resistant Depression and Suicidal Ideation**
Mu-Hong Chen (Taipei Veterans General Hospital)

Short Communications 4

Preclinical - Others

May 24, 2024 | 10:45-12:00 | Room 9 (G404)

Chair Joshua T. Kantrowitz (NYSPI/Columbia)

- SC4-1 **The Effect of Injection of Sertraline on Spike-Wave-Discharges and Stereotypic Behavior of Genetic Absence Epilepsy Rats from Strasbourg**
Berna Özen (Department of Medical Pharmacology, Marmara University School Of Medicine, Istanbul, Turkey)
- SC4-2 **Human microbiota from drug-naïve patients with obsessive-compulsive disorder drives behavioral symptoms and neuroinflammation via succinic acid in mice**
Dong-Dong Shi (Shanghai Jiao Tong University School of Medicine)
- SC4-3 **The Effect of $\alpha 6$ Subunit-Containing GABA_A Receptor Positive Allosteric Modulators on Striatal *Slitrk1*-knockdown Mice, A Novel Animal Model for Tourette Syndrome.**
Jung Chieh Du (Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan)
- SC4-4 **Homer 1a modulation in a rodent model of perinatal stress: translational inference from postsynaptic density Immediate-Early Gene-based network analyses. Implication for neurodevelopmental disorders.**
Licia Vellucci (Laboratory of Translational and Molecular Psychiatry, University Medical School of Naples "Federico II", Via Pansini 5, 80131 Naples, Italy)
- SC4-5 **Non-Invasive Functional PET – a Novel Approach to Assess Task-Specific Cerebral Glucose Metabolism**
Godber Mathis Godbersen (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria)
- SC4-6 **Activities of orexin neurons in motivational behavior**
Hiroyuki Mizoguchi (Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan)

Short Communications 5

Schizophrenia 1 - Clinical (1)

May 24, 2024 | 13:30-14:55 | Room 6 (G408)

Chair Bernhard Baune (University of Münster)

- SC5-1 **Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects**
Yuki Kikuchi (Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan)
- SC5-2 **Towards personalised pharmacological treatment in psychiatry: development of a digital tool to support evidence-based and patient-centred prescribing**
Toby Pillinger (Institute of Psychiatry, Psychology and Neuroscience)
- SC5-3 **Treatment Disengagement and APD Treatment in Early Psychosis: Results from EPINET – the Largest EP Network in the USA**
Alan Breier (Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA)
- SC5-4 **Combining pharmacotherapy and cognitive training in schizophrenia: effects on cognition and functional outcome**
Gabriele Sachs (Medical University of Vienna, Vienna, Austria)
- SC5-5 **Antipsychotic-induced extrapyramidal symptoms and tardive dyskinesia: analysis based on a spontaneous reporting system database in Japan**
Yosuke Saga (Medical Affairs Division, Janssen Pharma K.K, Tokyo, Japan)
- SC5-6 **Dysglycemia associated with antipsychotic use: a systematic review**
Emily Chen Chen Smith (University of Toronto, Toronto, Canada)
- SC5-7 **Higher Orexin-A Levels are associated with Better Treatment Response to Clozapine in Patients with Treatment Resistant Schizophrenia**
Po-Yu Chen (Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan)

Short Communications 6

Anxiety Disorders and Autism - Preclinical

May 24, 2024 | 13:30-14:45 | Room 7 (G407)

Chair Andrew Holmes (NIH)

- SC6-1 **Postpubertal stress selectively activates dopamine neurons projecting to the ventral striatum via disruption of reticular thalamic nucleus-nucleus reuniens-ventral hippocampal activity**
Anthony A Grace (University of Pittsburgh)
- SC6-2 **Antipsychotic agents in anxiety disorders: an umbrella review**
Rafael Freire (Department of Psychiatry and Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada)
- SC6-3 **alpha-2 adrenergic receptors in BNST regulate anxiety-like behavior via HPA axis in mice**
Teng Gao (Peking University Sixth Hospital, Peking University Institute of Mental Health, National Clinical Research Center for Mental Disorders)
- SC6-4 **Maternal exposure to air pollutant PM_{2.5} induces autistic-like behavior in offspring**
Sonata Suk-yu Yau (Department of Rehabilitation Sciences, Hong Kong Polytechnic University)
- SC6-5 **The epigenetic reader PHF21B modulates neurotransmission and synaptic plasticity-related genes in the hippocampus, and social memory**
Julio Licinio (State University of New York, Upstate Medical University)
- SC6-6 **Preclinical evidence supporting the role of Alogabat, a GABA_A-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders**
Maria Clemencia Hernandez (Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.)

Short Communications 7

Depression 2 - Clinical (2)

May 24, 2024 | 13:30-14:45 | Room 8 (G405)

Chair Gustavo Turecki (McGill University)

- SC7-1 **Extracellular vesicles in major depressive disorder and their relationship to treatment outcome**
Benjamin Eggerstorfer (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)
- SC7-2 **Serum Extracellular Vesicle-Derived hsa-miR-2277-3p and hsa-miR-6813-3p Are Potential Biomarkers for Major Depression**
Reiji Yoshimura (Department of Psychiatry, University of Occupational and Environmental Health)
- SC7-3 **Plasma Phosphoethanolamine Levels as a Biomarker for Monitoring Major Depressive Disorder**
Noriyuki Kawamura (Gyouki-Kai Medical Corporation)
- SC7-4 **Immune Markers as Predictors of Suicide Attempts in Persons with Major Depression After Hospital Discharge: A Prospective Study**
Faith Dickerson (Department of Psychology, Sheppard Pratt, Baltimore, United States)
- SC7-5 **A serial mediation model of psychological resilience related to depression severity among patients with major depressive disorders**
Reui Chun Wu (Department of Psychology, Asis university)
- SC7-6 **Changes in core depressive symptoms over time in peripartum women: a network analysis.**
Yuqun Zhang (School of Nursing, Nanjing University of Chinese Medicine)

Short Communications 8

Clinical - Others 1

May 24, 2024 | 13:30-14:55 | Room 9 (G404)

Chair Tomiki Sumiyoshi (National Center of Neurology and Psychiatry)

- SC8-1 **No differences in synaptic density in twins with autism and their non-autistic co-twins. However, are differences in SV2A binding potential in autistic brains a matter of white matter?**
Gina Griffioen-Järfalk (Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Region Stockholm, Stockholm, Sweden)
- SC8-2 **Plasma glial fibrillary acidic protein (GFAP) in astrocytes contributes to increases in the prevalence of autism spectrum disorders (ASD).**
Kunio Yui (Chiba University School of Medicine)
- SC8-3 **Association Between ADHD, Methylphenidate, and Precocious Puberty: A Nationwide Cohort Study**
Yi-Chun Liu (Department of Healthcare Administration, Asia University, Taichung, Taiwan)
- SC8-4 **Antidepressant effects of Silexan in patients with primary anxiety syndromes**
Lucie Bartova (Medical University of Vienna, Austria)
- SC8-5 **Borderline Personality Disorder and Inflammation: clinical and biological correlates**
Nadia Cattane (IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia)
- SC8-6 **Memory related structural and functional neural changes following a single infusion of Ketamine in PTSD**
Ilan Harpaz-Rotem (Yale University)
- SC8-7 **SHANK3 as risk factor for early-onset catatonia**
Dirk Marcel Dhossche (Inland Northwest Behavioral Health, Spokane, Washington, USA)

Short Communications 9

Depression 5 - Preclinical (1)

May 24, 2024 | 15:00-15:50 | Room 6 (G408)

Chair Yogesh Dwivedi (University of Alabama at Birmingham)

SC9-1 **Multimodal assessment of dopamine synthesis and BOLD-signaling in reward and punishment processing - A hybrid fPET/fMRI study**

Clemens Schmidt (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)

SC9-2 **Role of TAAR1 in the dentate gyrus in mediating chronic stress-induced impaired hippocampal neuronal plasticity in mice**

Yunai Su (Peking University Sixth Hospital & Peking University Institute of Mental Health)

SC9-3 **withdrawal**

SC9-4 **Behavioural control training and endocannabinoid enhancement lead to antidepressant/anxiolytic-like reversal of chronic stress-induced behavioural deficits**

Tadhg McManamon Strand (Department of Psychology, Memorial University of Newfoundland and Labrador, St. John's, NL, Canada)

Short Communications 10

Addiction Disorders 2 and Schizophrenia- Clinical (2)

May 24, 2024 | 15:00-16:15 | Room 7 (G407)

Chair Giovanni Martinotti ("G. d'Annunzio" University of Chieti-Pescara)

SC10-1 **Neurological Disorders in Consumers of the Home-Made, Artisanal Ephedrone Psychostimulants**

Nato Asatiani (Tbilisi State Medical University)

SC10-2 **Compulsive sexual behavior disorder and impulsivity**

Aviv Weinstein (Ariel University, Ariel, Israel)

SC10-3 **Age of onset affects relapse of alcohol use disorder: a 7-year retrospective cohort study**

Kai Zhang (Chaohu Hospital of Anhui Medical University, Hefei, China)

SC10-4 **Nerve growth factor gene polymorphisms may be associated with heroin dependence in women but do not mediate impulsivity and specific personality traits**

San-Yuan Huang (National defense medical center)

SC10-5 **Recent advances in Target Engagement Studies in Schizophrenia**

Joshua T Kantrowitz (NYSP/Columbia)

SC10-6 **Anti-NMDA Receptor Encephalitis: A Challenge in Psychiatric Settings**

GUNA Sekaran KANNIAH (TE Whati Ora Health New Zealand, Waikato Hospital)

Short Communications 11

Addiction Disorders and Anxiety Disorders - Translational

May 25, 2024 | 10:10-11:25 | Room 6 (G408)

Chair Yu-Li Liu (National Health Research Institutes)

SC11-1 **Effects of Chronic Methamphetamine Administration on Resting-State Functional Connectivity in Cynomolgus Monkeys**

Jiwon Chun (Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea)

SC11-2 **Distribution of dopamine pathway gene polymorphisms in subjects with different smoking behavior**

Evgeny N. Imyanitov (N.N. Petrov Institute of Oncology, Saint Petersburg, Russia)

SC11-3 **Brain responses to alcohol cues in youth at risk for substance use disorders (SUDs): a functional magnetic resonance imaging study.**

Maja Nikolic (McGill University)

SC11-4 **IL17RB genetic variants as biomarkers of acamprosate treatment response in patients with alcohol use disorder: a multi-omics study**

Ming-Fen Ho (Department of Psychiatry and Psychology, Mayo Clinic; Rochester, Minnesota, USA)

SC11-5 **Anxiety-Like Behaviour Study in Adult Rat Stress Model Induced by Light Dominant Exposure in Circadian Rhythm Disruption**

Shanty Rahayu Kusumawardani (Department of Applied Chemistry and Life Science, Toyohashi University of Technology)

SC11-6 **Inflammatory Cytokines during Pregnancy Predict Postpartum Anxiety: Findings from a Prospective Pregnancy Cohort**

Anna Sophie Rommel (Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA)

Short Communications 12

Depression 3 - Clinical (3)

May 25, 2024 | 10:10-11:35 | Room 7 (G407)

Chair Lakshmi YATHAM (The University of British Columbia)

SC12-1 **Redefining Recovery: Exploring Antidepressant Effects and Cognitive Impairment in Treatment Resistant Depression with Repetitive Transcranial Magnetic Stimulation**

Peter Giacobbe (Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Canada)

SC12-2 **Quantitative changes in Cognitive Flexibility induced by Transcranial Magnetic Stimulation in Depression: a preliminary report**

Anri WATANABE (Department of psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

SC12-3 **Slow but Steady: Short Communications Ketamine as an Effective Adjunct in Depression, Anxiety and PTSD**

William Sulis (McMaster University)

SC12-4 **Repurposing of gamma-hydroxybutyrate in depression: a randomized placebo-controlled proof-of-concept clinical trial**

Francesco Bavato (Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Switzerland)

SC12-5 **Disturbed sex hormones milieu in males and females with major depressive disorder and low-grade inflammation**

Giulia Lombardo (King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, Maurice Wohl Clinical Neuroscience Institute, Kings College London, SE5 9RT, UK)

SC12-6 **Efficacy of low-dose interleukin 2 as add-on in the treatment of unipolar and bipolar depression.**

Sara Poletti (Psychiatry and Clinical Psychobiology, Division of Neuroscience, Scientific Institute Ospedale San Raffaele, Milano)

SC12-7 **New developments in the multi-omics prediction of treatment response prediction in Psychiatry**

Bernhard T Baune (University of Münster)

Short Communications 13

Schizophrenia and Pain - Preclinical

May 25, 2024 | 10:10-11:10 | Room 8 (G405)

Chair Rachel Hill (Monash University)

SC13-1 **Clinically predictive modulation of cognitive impairments in mouse touchscreen tasks**

Daisy Spark (The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia)

SC13-2 **The preventive effects of ultra-micronized palmitoylethanolamide (PEA) in a preclinical model of schizophrenia.**

Courtney Leigh Clarke (Memorial University of Newfoundland and Labrador)

SC13-3 **A Rho-kinase 2 selective inhibitor KD025 ameliorates schizophrenia-like behaviors in MK-801-treated mice**

Rinako Tanaka (Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan)

SC13-4 **Effect of acute Psilocybin on thermal and Neuropathic Pain in rodents**

Martha Lopez Canul (McGill University, Department of Psychiatry and Alan Edwards Centre for Research on Pain, Montréal, QC, Canada)

SC13-5 **“Immunosuppressive” Cannabinoid CB2 receptors take “Immunoactive” role in high-fat diet evoked systemic inflammatory response**

Chihiro Nozaki (Global Center for Science and Engineering, Waseda University, Tokyo, Japan)

Short Communications 14

Clinical - Others 2

May 25, 2024 | 10:10-11:25 | Room 9 (G404)

Chair Yoshiya Moriguchi (Lundbeck Japan K.K.)

SC14-1 **Reproducible Effective Connectivity and Its Relationship to Cognition: A Simultaneous Resting-State PET/MRI Investigation**

Kai-Chun Yang (Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan)

SC14-2 **The brain on hormones: Effects of gender-affirming hormone therapy on gray matter density and microstructure**

Patricia Anna Handschuh (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)

SC14-3 **The relationship of brain neurotransmitter levels and sex hormones**

Benjamin Spurny (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria)

SC14-4 **Sex differences in brain excitability revealed by concurrent iTBS/fNIRS**

Rebecca Laidi Kan (Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China)

SC14-5 **withdrawal**

SC14-6 **Psychosomatic Symptoms in Type 2 Diabetes Patients: A Network Analysis**

Wei Xu (Department of Psychosomatics and Psychiatry, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China)

Short Communications 15

Schizophrenia and Autism - Translational

May 25, 2024 | 13:00-14:00 | Room 6 (G408)

Chair Suresh Sundram (Monash University)

SC15-1 **Acute inflammation induced by ultra-low dose lipopolysaccharide and restraint stress improve positive symptom-like behavior in a mouse model of schizophrenia by different mechanisms**

Rikuto Christopher Shinohara (Department of Psychiatry, Kushiro City General Hospital, Kushiro, Japan)

SC15-2 **Genome-Wide Association Study Implicates Lipid Pathway Dysfunction in Antipsychotic Induced Weight Gain: Multi-Ancestry Validation**

Yundan Liao (Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China)

SC15-3 **Susceptible pyramidal neurons in primate dorsolateral prefrontal cortex express an enriched calcium interactome: Critical role of calbindin and Cav_{1.2} in higher-order cognition**

Dibyadeep Datta (Department of Neuroscience, Yale University, New Haven, CT USA)

SC15-4 **Automated analysis of rodent behavior using IntelliProfiler: a potential tool for studying neurodevelopmental disorder-like model mice**

Shohei Ochi (Department of Developmental Neuroscience, Tohoku University Graduate School of Medicine, Miyagi, Japan)

SC15-5 **Whole Genome Sequencing Analysis of Japanese ASD Trios: Unraveling Pathogenic Variants**

Sawako Furukawa (Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan)

Short Communications 16

COVID-19 - Clinical

May 25, 2024 | 13:00-14:00 | Room 7 (G407)

Chair Pierre Blier (CINP)

SC16-1 **Impact of COVID-19 Infection on White Matter microstructural alterations in Healthy population and Major Depressive Disorder: A Multimodal MRI Study**

Taipeng Sun (Department of Psychosomatics and Psychiatry, ZhongDa Hospital; School of Medicine, Southeast University, Nanjing, Jiangsu, China)

- SC16-2 **Mechanisms of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS) and long COVID with predominant fatigue: a magnetic resonance spectroscopy study of the brain and muscle at 7 Tesla.**
Beata Godlewska (Department of Psychiatry, University of Oxford, Oxford, UK)
- SC16-3 **Risk Factors, Symptomatology, and Predictors of Mortality among COVID-19 Inpatients Presenting with Delirium Symptoms in a Tertiary Hospital in the Philippines**
Sedric John Factor (Department of Psychiatry & Behavioral Communications Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines)
- SC16-4 **Chronic post-COVID neuropsychiatric symptom clusters do not share the same risk factors in a cohort infected by the Omicron variant**
Steven Wai Ho Chau (Chinese University of Hong Kong)
- SC16-5 **Correlates of anxiety and depressive symptoms in inpatients with COVID-19 in Taiwan**
WEI-CHEN LEE (Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan)

Short Communications 17

Depression 4 - Clinical (4)

May 25, 2024 | 13:00-14:00 | Room 8 (G405)

Chair Takeshi Inoue (Tokyo Medical University)

- SC17-1 **Disease Progression Modeling of Brain Macrostructure in Treatment-Resistant Depression**
Koki Takahashi (Department of Neuropsychiatry, Keio University School of Medicine)
- SC17-2 **Withdrawal**
- SC17-3 **Volumetric assessment of individual thalamic nuclei in patients with drug-naïve, first-episode major depressive disorder**
Enkhmurun Chibaatar (Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan)
- SC17-4 **Functional dynamics of serotonin synthesis during monetary reward and punishment processing – A hybrid fPET/fMRI study.**
Leo Robert Silberbauer (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)
- SC17-5 **Lockdown-associated changes in the default mode network in depression and healthy individuals during the COVID-19 pandemic in Austria**
Jakob Unterholzner (Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria)

Short Communications 18

Others 1

May 25, 2024 | 13:00-14:15 | Room 9 (G404)

Chair Hiroko Kotajima (Tokyo Metropolitan Institute of Medical Science)

- SC18-1 **Single-cell analysis identified cell-type-specific and converged pathways of autism spectrum disorder.**
Jun Nomura (Department of Physiology, Kobe University School of Medicine, Kobe, Japan)
- SC18-2 **Absence of FMRP modulates brain development in a sex-specific manner**
Takako Kikkawa (Department of Developmental Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan)
- SC18-3 **The effects of acute cannabis with and without cannabidiol on neural reward anticipation in adults and adolescents**
Martine Skumlien (Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK)
- SC18-4 **Cannabinoid receptor type 1-regulated cell death depending on its subcellular localization in human neuroblastoma cell**
Kazuaki Mori (Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan)
- SC18-5 **The impact of Sleep Jet Lag on Depression differed by Sex and Age ~ Evidence from 27,916 Taiwan Biobank Participants**
Shaw-Ji Chen (Taitung Mackay Memorial Hospital)

- SC18-6 **Methoxphenidine, a designer drug or a possible route for research to depression treatment?**
Bronislav Jursek (Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds,
University of chemistry and technology in Prague, Prague, Czech Republic)

Short Communications 19

Schizophrenia 2 - Clinical (2)

May 25, 2024 | 14:30-15:10 | Room 7 (G407)

Chair Toru Nishikawa (Showa Medical University/Kyoto Prefectural University of Medicine)

- SC19-1 **Altered functional connectivity of fusiform gyrus and disorganization domain as core correlates of treatment-resistant schizophrenia: a resting-state fMRI study**

Mariateresa Ciccarelli (Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy)

- SC19-2 **Neuroimaging stratification reveals a brain pathway linking environmental stresses to psychotic symptoms in the first-degree relatives of patients with schizophrenia**

Qiang Luo (Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China)

- SC19-3 **Stimulating the prefrontal cortex to reduce hyperreactivity to stress in people at risk of schizophrenia**

Jerome Brunelin (INSERM U1028, CNRS UMR5292, CRNL)

Short Communications 20

Depression 7 - Translational (1)

May 25, 2024 | 14:30-15:30 | Room 8 (G405)

Chair Tadafumi Kato (Juntendo University)

- SC20-1 **Antidepressant Augmentation Strategies Targeting Signal transduction Proof of Concept in Animal Models**

Eleni T Tzavara (CNRS UMR8002 Université Paris Cité)

- SC20-2 **Translating 5-HT₄R agonism into mental illness: potential clinical applications for mood disorder and cognitive impairment**

Angharad de Cates (Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK)

- SC20-3 **Opioid Effects of Ketamine: Research and Clinical Implications**

Alan Schatzberg (Stanford University)

- SC20-4 **Immunometabolic features mapping clinical domains in stress related psychiatric disorders: implications for personalized interventions.**

Annamaria Cattaneo (University of Milan and IRCCS Fatebenefratelli Hospital)

- SC20-5 **withdrawal**

Short Communications 21

Addiction Disorders 3 - Preclinical

May 26, 2024 | 10:45-11:45 | Room 7 (G407)

Chair Anthony A. Grace (International Journal of Neuropsychopharmacology)

- SC21-1 **Ghrelin signalling mediates sex differences in midbrain control of binge drinking**

Leigh C Walker (Florey Institute of Neuroscience and Mental Health)

- SC21-2 **BehaviShort Communications and electrophysiological effects of lysergic acid diethylamide (LSD) in a mouse model of alcohol use disorder (AUD)**

Danilo De Gregorio (Vita Salute San Raffaele University)

- SC21-3 **Cocaine- and amphetamine-regulated transcript (CART) mediates sex differences in binge drinking through central taste circuits**

Xavier James Maddern (Florey Institute of Neuroscience and Mental Health, Parkville, Australia)

SC21-4 ***Npas4* Enhancer RNA forms DNA:RNA hybrid R-loop to control reward-related behavior**
Short Communications adaptation through activity-dependent gene expression

Makoto Taniguchi (Department of Neuroscience, MEDICAL UNIVERSITY OF SOUTH CAROLINA)

SC21-5 **Developmental nicotine exposure and cognitive vulnerability: Is the immune system involved?**

Vinay Parikh (Department of Psychology and Neuroscience, Temple University, Philadelphia, USA)

Short Communications 22

Translational - Others

May 26, 2024 | 10:45-11:45 | Room 8 (G405)

Chair Shinya Kasai (Tokyo Metropolitan Institute of Medical Science)

SC22-1 **Anti-compulsive action of escitalopram in deer mice parallels decreased plasma lipopolysaccharide and increased frontal-cortical and striatal tryptophan, but not serotonin concentrations**

De Wet Wolmarans (Center of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University)

SC22-2 **Application of Machine Learning to Large Scale Electronic Health Record Data Predicts Risk to Readmission for Suicide Attempt**

Zachary Aaron Kaminsky (University of Ottawa Institute of Mental Health Research)

SC22-3 **TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies.**

Livia De Picker (Faculty of Medicine and Health Sciences, Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium)

SC22-4 **Ergogenic words: how placebos change our brain.**

Elisa Carlino (Department of Neuroscience Rita Levi Montalcini, University of Turin, Italy)

SC22-5 **A new hope for multiple system atrophy: A translational research of a novel NMDAR receptor modulator from preclinical models to patients**

Da-Zhong Luo (Department of Psychology, National Taiwan University, Taipei, Taiwan)

Short Communications 23

Depression 6 - Preclinical (2)

May 26, 2024 | 10:45-11:45 | Room 9 (G404)

Chair Nasser Haddjeri (INSERM)

SC23-1 **Psilocybin mitigates behavior despair and cognitive recognition impairments by regulating the hypothalamic-pituitary-adrenal (HPA) axis via the brain-derived neurotrophic factor (BDNF) signaling pathway mediated by the endocannabinoid system (ECS).**

Zitong Wang (Department of Psychiatry, University of Alberta, Edmonton, Canada)

SC23-2 **Adiponectin elicits rapid-antidepressant effects in chronically stressed mice in association with increased glutamatergic activity in the mPFC**

Douglas Affonso Formolo (Department of Rehabilitation Sciences, The Hong Kong Polytechnic University (PolyU), Hong Kong, China)

SC23-3 **Effects on the thalamus and insular cortex during vocal emotion processing by modafinil and bupropion: A pharmacological MRI study**

Michihiko Koeda (Department of Neuropsychiatry, Nippon Medical School Tama-Nagayama Hospital)

SC23-4 **The interplay between brain neurotransmitters and opioid systems in Major Depression (MD) and comorbid MD and Generalized Anxiety.**

Irina N Trofimova (McMaster University)

SC23-5 **Psychosocial and genomic drivers of mental well-being in university students: novel findings from a world-first longitudinal study**

Divya Mehta Mehta (Queensland University of Technology)

Short Communications 24

Others 2

May 26, 2024 | 14:50-15:50 | Room 5 (G409)

Chair Yukio Ago (Hiroshima University)

SC24-1 **Using AI Approaches for Predicting Brain Ageing Changes in Schizophrenia**

Lan-Ying Huang (Ph.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 402, Taiwan)

SC24-2 **Truncated HS3ST4 expressed downstream of chronic pain-associated single nucleotide polymorphisms regulates transcriptional promoter activity**

Seii Ohka (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

SC24-3 **Consensus Recommendations on the Recognition, Assessment, and Management of Tardive Dyskinesia in countries from Southeast Asia**

Chee Yoon (Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders (ChulaPD) Chulalongkorn University, Bangkok, Thailand)

SC24-4 **Ghrelin protects dopaminergic neurons against MPTP neurotoxicity through promoting autophagy and inhibiting endoplasmic reticulum mediated apoptosis**

Huiqing Wang (Southeast University)

SC24-5 **Effects of neuromodulation on local prefrontal circuits in mouse models for psychiatric disorders.**

Minobu Ikehara (Department of psychiatry, Nara Medical University)

Short Communications 25

Depression 8 - Translational (2)

May 26, 2024 | 14:50-15:40 | Room 6 (G408)

Chair Tetsuya Suhara (National Institutes for Quantum Science and Technology)

SC25-1 **The interplay between nutrition and inflammation in depression: Omega-3 fatty acids for anxiety and depression in Long COVID**

Kuan-Pin Su (China Medical University, Taichung, TAIWAN)

SC25-2 **Multi-Omics Profiling of Human Hippocampus Neurogenic Niche to Decipher the Neurobiology of Major Depression**

Maura Boldrini (Columbia University)

SC25-3 **Neuroanatomical biotyping by semi-supervised machine learning focusing on heterogeneity in treatment-resistant depression**

Nobuaki Hondo (Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Keio University)

SC25-4 **Whole-transcriptome immunometabolic pathways are involved in major depressive disorder and its phenotypic heterogeneity**

Luca Sforzini (King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, Maurice Wohl Clinical Neuroscience Institute, Kings College London, SE5 9RT, UK.)

Short Communications 26

Bipolar Disorders - Translational

May 26, 2024 | 14:50-15:50 | Room 7 (G407)

Chair Kazuki Nagayasu (Kyoto University)

SC26-1 **Human plasma transcriptome analysis in brain-enriched extracellular vesicles with bipolar disorder and major depression**

Yuki Kageyama (Department of Neuropsychiatry, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan)

SC26-2 **Causal relationships between structural brain imaging markers in adolescence and psychiatric disorders in adulthood**

Yen-Feng Lin (National Health Research Institutes)

- SC26-3 **Reduced AMPA receptors in the cerebellum induces bipolar mania via the ventral tegmental area**
Wataru Ota (Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan)
- SC26-4 **Utilizing AI models to identify and predict mood transition patterns in patients with bipolar disorder**
Xiaoyang Feng (Peking University 6th Hospital)
- SC26-5 **Direct induction of microglia-like cells from human monocytes: A novel cellular tool for translational research of neuropsychiatric disorders**
Masahiro Ohgidani (Department of Functional Anatomy and Neuroscience, Asahikawa Medical University)

Short Communications 27

Schizophrenia 3 - Clinical (3)

May 26, 2024 | 14:50-15:40 | Room 8 (G405)

Chair Hidenori Yamasue (Hamamatsu University School of Medicine)

- SC27-1 **Acute Effects of Diazepam on Hippocampal Resting Cerebral Blood Flow in Individuals at Clinical High-Risk for Psychosis**
Nicholas Livingston (Institute of Psychiatry, Psychology, and Neuroscience, King's College London)
- SC27-2 **Minimum effective dose of aripiprazole during maintenance for patients in remitted state of psychosis guided by an exponential tapering method: verification by plasma drug concentration**
CHUN-I LIU (Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan)
- SC27-3 **CYP2D6 genotypes and treatment failure with risperidone or aripiprazole: results from a one-year longitudinal study**
Chin B Eap (Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Hospital of Cery, Department of Psychiatry, Lausanne University Hospital, University of Lausanne)
- SC27-4 **Vaccine response and immunity in patients with psychotic disorders: prospective study of SARS-CoV-2 and Pneumococcal vaccination**
Atheeshaan Arumuham (Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, De Crespigny Park, London, SE5 8AF, UK)